PYC Therapeutics Limited (PYC.AX)
AUD 1.41
(-6.0%)
AUD 1.41
(-6.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 91.23 Million AUD | 145.49% |
| 2023 | 37.16 Million AUD | -18.05% |
| 2022 | 45.35 Million AUD | -21.73% |
| 2021 | 57.94 Million AUD | 83.67% |
| 2020 | 31.54 Million AUD | 370.75% |
| 2019 | 6.7 Million AUD | 96.0% |
| 2018 | 3.41 Million AUD | -66.96% |
| 2017 | 10.34 Million AUD | 42.42% |
| 2016 | 7.26 Million AUD | 306.85% |
| 2015 | 1.78 Million AUD | -60.53% |
| 2014 | 4.52 Million AUD | 99.97% |
| 2013 | 2.26 Million AUD | -35.27% |
| 2012 | 3.49 Million AUD | -38.26% |
| 2011 | 5.66 Million AUD | 260.57% |
| 2010 | 1.57 Million AUD | -54.98% |
| 2009 | 3.48 Million AUD | -0.9% |
| 2008 | 3.51 Million AUD | -0.42% |
| 2007 | 3.53 Million AUD | 24.78% |
| 2006 | 2.83 Million AUD | -53.45% |
| 2005 | 6.08 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 39.75 Million AUD | 0.0% |
| 2024 Q4 | 91.23 Million AUD | 0.0% |
| 2024 FY | 91.23 Million AUD | 145.49% |
| 2023 FY | 37.16 Million AUD | -18.05% |
| 2023 Q4 | 37.16 Million AUD | 0.0% |
| 2023 Q2 | 31.64 Million AUD | 0.0% |
| 2022 Q2 | 51.83 Million AUD | 0.0% |
| 2022 Q4 | 45.35 Million AUD | 0.0% |
| 2022 FY | 45.35 Million AUD | -21.73% |
| 2021 Q4 | 57.94 Million AUD | 0.0% |
| 2021 Q2 | 63.24 Million AUD | 0.0% |
| 2021 FY | 57.94 Million AUD | 83.67% |
| 2020 Q2 | 35.93 Million AUD | 0.0% |
| 2020 FY | 31.54 Million AUD | 370.75% |
| 2020 Q4 | 31.54 Million AUD | 0.0% |
| 2019 Q4 | 6.7 Million AUD | 0.0% |
| 2019 Q2 | 10.98 Million AUD | 0.0% |
| 2019 FY | 6.7 Million AUD | 96.0% |
| 2018 Q4 | 3.41 Million AUD | 0.0% |
| 2018 FY | 3.41 Million AUD | -66.96% |
| 2018 Q2 | 7.34 Million AUD | 0.0% |
| 2017 Q4 | 10.34 Million AUD | 0.0% |
| 2017 Q2 | 6.5 Million AUD | 0.0% |
| 2017 FY | 10.34 Million AUD | 42.42% |
| 2016 FY | 7.26 Million AUD | 306.85% |
| 2016 Q4 | 7.26 Million AUD | 0.0% |
| 2016 Q2 | 9.93 Million AUD | 0.0% |
| 2015 FY | 1.78 Million AUD | -60.53% |
| 2015 Q4 | 1.78 Million AUD | 0.0% |
| 2015 Q2 | 4.53 Million AUD | 0.0% |
| 2014 FY | 4.52 Million AUD | 99.97% |
| 2014 Q4 | 4.52 Million AUD | 0.0% |
| 2014 Q2 | 7.35 Million AUD | 0.0% |
| 2013 Q1 | 4.18 Million AUD | 19.6% |
| 2013 FY | 2.26 Million AUD | -35.27% |
| 2013 Q4 | 2.26 Million AUD | 0.0% |
| 2013 Q3 | 2.26 Million AUD | -45.88% |
| 2013 Q2 | 4.18 Million AUD | 0.0% |
| 2012 FY | 3.49 Million AUD | -38.26% |
| 2012 Q4 | 3.49 Million AUD | 0.0% |
| 2011 FY | 5.66 Million AUD | 260.57% |
| 2011 Q4 | 5.66 Million AUD | 0.0% |
| 2010 Q4 | 1.57 Million AUD | 0.0% |
| 2010 FY | 1.57 Million AUD | -54.98% |
| 2009 FY | 3.48 Million AUD | -0.9% |
| 2009 Q4 | 3.48 Million AUD | 0.0% |
| 2008 Q4 | 3.51 Million AUD | 0.0% |
| 2008 FY | 3.51 Million AUD | -0.42% |
| 2007 Q4 | 3.53 Million AUD | 0.0% |
| 2007 FY | 3.53 Million AUD | 24.78% |
| 2006 FY | 2.83 Million AUD | -53.45% |
| 2006 Q4 | 2.83 Million AUD | 0.0% |
| 2005 FY | 6.08 Million AUD | 0.0% |
| 2005 Q4 | 6.08 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 25.55 Million AUD | -257.072% |
| Anatara Lifesciences Ltd | 1.67 Million AUD | -5358.757% |
| Zelira Therapeutics Limited | 5.18 Million AUD | -1660.207% |
| Biome Australia Limited | 8.27 Million AUD | -1002.346% |
| Patrys Limited | 4.16 Million AUD | -2092.409% |
| Orthocell Limited | 26.61 Million AUD | -242.807% |
| Imugene Limited | 151.39 Million AUD | 39.736% |
| Noxopharm Limited | 6.78 Million AUD | -1244.96% |
| Chimeric Therapeutics Limited | 15.27 Million AUD | -497.381% |
| Prescient Therapeutics Limited | 20.39 Million AUD | -347.406% |
| Proteomics International Laboratories Limited | 10.87 Million AUD | -738.969% |
| Cynata Therapeutics Limited | 8.38 Million AUD | -987.693% |
| CSL Limited | 56.93 Billion AUD | 99.84% |
| Arovella Therapeutics Limited | 13.28 Million AUD | -586.797% |
| Bio-Gene Technology Limited | 3.15 Million AUD | -2787.68% |
| Clinuvel Pharmaceuticals Limited | 231.12 Million AUD | 60.524% |
| Starpharma Holdings Limited | 36.81 Million AUD | -147.837% |
| Nanollose Limited | 241.95 Thousand AUD | -37609.644% |
| Memphasys Limited | 12.43 Million AUD | -634.013% |
| Invex Therapeutics Ltd | 6.12 Million AUD | -1390.819% |
| NeuroScientific Biopharmaceuticals Limited | 5.43 Million AUD | -1578.458% |
| Amplia Therapeutics Limited | 14.84 Million AUD | -514.606% |
| Botanix Pharmaceuticals Limited | 112.46 Million AUD | 18.873% |
| Island Pharmaceuticals Limited | 2.56 Million AUD | -3457.804% |
| Race Oncology Limited | 20.22 Million AUD | -351.04% |
| Nyrada Inc. | 5.9 Million AUD | -1444.52% |
| Telix Pharmaceuticals Limited | 398.3 Million AUD | 77.093% |
| Dimerix Limited | 32.07 Million AUD | -184.423% |
| PharmAust Limited | 11.12 Million AUD | -720.136% |
| Immutep Limited | 147.44 Million AUD | 38.122% |
| Clarity Pharmaceuticals Ltd | 154.62 Million AUD | 40.995% |
| Alterity Therapeutics Limited | 19.22 Million AUD | -374.615% |
| BTC Health Limited | 5.14 Million AUD | -1672.039% |
| Acrux Limited | 8.96 Million AUD | -917.95% |
| Neuren Pharmaceuticals Limited | 247.97 Million AUD | 63.206% |
| Biotron Limited | 493.47 Thousand AUD | -18389.017% |
| Tissue Repair Ltd | 19.38 Million AUD | -370.556% |
| AdAlta Limited | 5.57 Million AUD | -1537.159% |
| Radiopharm Theranostics Limited | 72.03 Million AUD | -26.657% |
| Hexima Limited | 2.26 Million AUD | -3921.097% |
| AnteoTech Limited | 9.38 Million AUD | -872.573% |
| Paradigm Biopharmaceuticals Limited | 27.39 Million AUD | -233.105% |
| Recce Pharmaceuticals Ltd | 6.36 Million AUD | -1332.408% |
| Avecho Biotechnology Limited | 7.31 Million AUD | -1146.55% |
| Actinogen Medical Limited | 21.31 Million AUD | -328.113% |
| Immuron Limited | 15.54 Million AUD | -486.746% |
| Argenica Therapeutics Limited | 16.37 Million AUD | -457.097% |